FDA approval date
The FDA announced approval of Foundayo (orforglipron) on April 1, 2026, under the Commissioner’s National Priority Voucher pilot program.
Why the announcement stood out
The FDA described the decision as the first new molecular entity approval under that program and noted the accelerated review timeline in its public announcement.
What approval does not mean
FDA approval does not mean a medicine is suitable for everyone. Official labeling and clinician guidance remain important for safety, eligibility, and correct use.
References used
FDA press announcementDrugs.com FoundayoWebMD FoundayoForm Health FoundayoThis page does not provide personal medical advice.